Bristol signs clinical trial collaboration with PsiOxus
Bristol-Myers Squibb Co. formed an alliance to test the safety, tolerability, and preliminary efficacy of a combination of its Opdivo (nivolumab) with PsiOxus Therapeutics Ltd.'s enadenotucirev in Phase I studies for multiple tumors at later stages.
- R&D and Marketing (Licensing)
- Trial Collaborations
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.